Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTACK: TAA-T Therapy for High-Risk Solid Tumors
NCT05238792Phase 1Recruiting
- Sponsor
- Children's National Research Institute
- Start
- Nov 2021
- Primary completion
- Oct 2028
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial in solid tumor (3 arms), sponsored by Children's National Research Institute. Primary endpoint: Safety of administering partially HLA-matched TAA-T cells at 45 days. Started Nov 2021; status: recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05238792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238792.